Wakamoto Pharmaceutical Co (TSE:4512) Beneish M-Score: -2.09 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4512 Wakamoto Pharmaceutical Co Ltd TSE:4512
63 GF Score
Price 円278.00
GF Value 円319.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Wakamoto Pharmaceutical Co Beneish M-Score?

Wakamoto Pharmaceutical Co TSE:4512 63 Beneish M-Score is -2.09 as of Jul. 15, 2026. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks worse than 75.19% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.09 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Wakamoto Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

TSE:4512' s Beneish M-Score Range Over the Past 10 Years
Min: -3.07   Med: -2.48   Max: -2.09
Current: -2.09

During the past 13 years, the highest Beneish M-Score of Wakamoto Pharmaceutical Co was -2.09. The lowest was -3.07. And the median was -2.48.


Wakamoto Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Wakamoto Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wakamoto Pharmaceutical Co Beneish M-Score Chart

Wakamoto Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.57 -2.45 -2.42 -2.46 -2.09

Wakamoto Pharmaceutical Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.42 0.00 -2.46 0.00 -2.09

TSE:4512 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wakamoto Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Wakamoto Pharmaceutical Co's Beneish M-Score falls into.


TSE:4512
63GF Score
Wakamoto Pharmaceutical Co Ltd TSE:4512
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wakamoto Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Wakamoto Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0574+0.528 * 0.9739+0.404 * 1.0352+0.892 * 1.2718+0.115 * 1.0652
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * 0.043281-0.327 * 1.3598
=-2.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was 円3,522 Mil.
Revenue was 円9,907 Mil.
Gross Profit was 円4,730 Mil.
Total Current Assets was 円9,672 Mil.
Total Assets was 円16,500 Mil.
Property, Plant and Equipment(Net PPE) was 円3,662 Mil.
Depreciation, Depletion and Amortization(DDA) was 円443 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円2,781 Mil.
Long-Term Debt & Capital Lease Obligation was 円262 Mil.
Net Income was 円227 Mil.
Gross Profit was 円0 Mil.
Cash Flow from Operations was 円-487 Mil.
Total Receivables was 円2,619 Mil.
Revenue was 円7,789 Mil.
Gross Profit was 円3,622 Mil.
Total Current Assets was 円8,908 Mil.
Total Assets was 円15,003 Mil.
Property, Plant and Equipment(Net PPE) was 円3,313 Mil.
Depreciation, Depletion and Amortization(DDA) was 円430 Mil.
Selling, General, & Admin. Expense(SGA) was 円0 Mil.
Total Current Liabilities was 円2,035 Mil.
Long-Term Debt & Capital Lease Obligation was 円0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3521.976 / 9906.84) / (2618.883 / 7789.461)
=0.35551 / 0.336209
=1.0574

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3622.471 / 7789.461) / (4730.482 / 9906.84)
=0.465048 / 0.477497
=0.9739

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (9671.819 + 3661.676) / 16499.607) / (1 - (8908.257 + 3313.368) / 15002.709)
=0.19189 / 0.185372
=1.0352

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=9906.84 / 7789.461
=1.2718

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(430.343 / (430.343 + 3313.368)) / (442.932 / (442.932 + 3661.676))
=0.114951 / 0.107911
=1.0652

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 9906.84) / (0 / 7789.461)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((261.54 + 2781.298) / 16499.607) / ((0 + 2034.774) / 15002.709)
=0.184419 / 0.135627
=1.3598

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(227.215 - 0 - -486.912) / 16499.607
=0.043281

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Wakamoto Pharmaceutical Co has a M-score of -2.09 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.09 mean?
Wakamoto Pharmaceutical Co (TSE:4512) has a Beneish M-Score of -2.09 as of Jul. 15, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Wakamoto Pharmaceutical Co and its competitors. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #685 out of 911 companies in the Drug Manufacturers industry, placing it in the top 75.2%.
Is Wakamoto Pharmaceutical Co's Beneish M-Score too high?
Wakamoto Pharmaceutical Co's current Beneish M-Score is -2.09. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #685 out of 911 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #685 out of 911 companies for Beneish M-Score. This places Wakamoto Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Wakamoto Pharmaceutical Co and its competitors. Wakamoto Pharmaceutical Co's current Beneish M-Score is -2.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.10, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current Beneish M-Score is -2.09. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Beneish M-Score is -2.09 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?

Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued. The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.10. GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for TSE:4512:

  • Beneish M-Score: -2.09
  • GF Value™: 円319.10 vs. price of 円278.00 (12.9% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Wakamoto Pharmaceutical Co Business Description

Address 2-2-2, Nihonbashi Honcho, Chuo-ku, Tokyo, JPN, 103-8330
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score

Get the complete analysis for TSE:4512

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円278.00
Price
円319.10
GF Value